- Barrons.com•1 hour ago
While fundamentals of the group appear stable following the recent 2Q16 earnings season (see our recent note here) and valuations are attractive, we acknowledge that ongoing negative headlines may stunt the fledgling “recovery” that has started to take place in the space over the past couple of months. More broadly, while media scrutiny/political headlines around drug pricing could result in continued volatility through the elections, we continue to see the group positioned for a recovery over time, with valuations inexpensive on almost any metric (~8x 2017 EPS) and improving fundamentals after a challenging 1H/16.
- MarketWatch•1 hour ago
Mylan’s EpiPen monopoly could end in 2017 as the Food and Drug Administration may speed up approval of a generic competitor.
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||51.68 x 400|
|Ask||51.69 x 500|
|Day's Range||51.13 - 52.29|
|52wk Range||48.01 - 66.55|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||34.44|
|Avg Vol (3m)||5,648,640|
|Dividend & Yield||1.36 (2.56%)|